National Trends in Management of Pathologic Stage III Melanoma

Kristen E. Rhodin; Norma E. Farrow; Maria Xu; Jay Lee; Douglas S. Tyler; Georgia M. Beasley

doi:10.1245/s10434-023-13101-6

National Trends in Management of Pathologic Stage III Melanoma

Kristen E. Rhodin, Norma E. Farrow, Maria Xu, Jay Lee, Douglas S. Tyler, Georgia M. Beasley

Surgery

Research output: Contribution to journal › Comment/debate › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	2586-2589
Number of pages	4
Journal	Annals of surgical oncology
Volume	30
Issue number	5
DOIs	https://doi.org/10.1245/s10434-023-13101-6
State	Published - May 2023

ASJC Scopus subject areas

Surgery
Oncology

Access to Document

10.1245/s10434-023-13101-6

Cite this

@article{15f7a438d63d424cb17d6646c5e0eb40,

title = "National Trends in Management of Pathologic Stage III Melanoma",

author = "Rhodin, {Kristen E.} and Farrow, {Norma E.} and Maria Xu and Jay Lee and Tyler, {Douglas S.} and Beasley, {Georgia M.}",

note = "Funding Information: Georgia Beasley has received clinical trial funding paid to Duke University from Delcath, Istari, Replimune, Oncosec, and Checkmate, and has served on a one-time advisory board for Cardinal Health and Regeneron. She is also supported by NIH K08 CA237726-01A1. Kristen E. Rhodin is supported by NIH 1R38AI140297. Norma E. Farrow, Maria Xu, Jay Lee, and Douglas S. Tyler have no disclosures to declare. ",

year = "2023",

month = may,

doi = "10.1245/s10434-023-13101-6",

language = "English (US)",

volume = "30",

pages = "2586--2589",

journal = "Annals of surgical oncology",

issn = "1068-9265",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "5",

}

TY - JOUR

T1 - National Trends in Management of Pathologic Stage III Melanoma

AU - Rhodin, Kristen E.

AU - Farrow, Norma E.

AU - Xu, Maria

AU - Lee, Jay

AU - Tyler, Douglas S.

AU - Beasley, Georgia M.

N1 - Funding Information: Georgia Beasley has received clinical trial funding paid to Duke University from Delcath, Istari, Replimune, Oncosec, and Checkmate, and has served on a one-time advisory board for Cardinal Health and Regeneron. She is also supported by NIH K08 CA237726-01A1. Kristen E. Rhodin is supported by NIH 1R38AI140297. Norma E. Farrow, Maria Xu, Jay Lee, and Douglas S. Tyler have no disclosures to declare.

PY - 2023/5

Y1 - 2023/5

UR - http://www.scopus.com/inward/record.url?scp=85146292600&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85146292600&partnerID=8YFLogxK

U2 - 10.1245/s10434-023-13101-6

DO - 10.1245/s10434-023-13101-6

M3 - Comment/debate

C2 - 36641513

AN - SCOPUS:85146292600

SN - 1068-9265

VL - 30

SP - 2586

EP - 2589

JO - Annals of surgical oncology

JF - Annals of surgical oncology

IS - 5

ER -

National Trends in Management of Pathologic Stage III Melanoma

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this